These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34786956)

  • 1. Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.
    Konno SI; Nikaido T; Markman JD; Ohta M; Machida T; Isogawa N; Yoshimatsu H; Viktrup L; Brown MT; West CR; Verburg KM
    Pain Manag; 2022 Apr; 12(3):323-335. PubMed ID: 34786956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
    Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain.
    Kivitz AJ; Gimbel JS; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2013 Jul; 154(7):1009-21. PubMed ID: 23628600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.
    Markman JD; Bolash RB; McAlindon TE; Kivitz AJ; Pombo-Suarez M; Ohtori S; Roemer FW; Li DJ; Viktrup L; Bramson C; West CR; Verburg KM
    Pain; 2020 Sep; 161(9):2068-2078. PubMed ID: 32453139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain.
    Gimbel JS; Kivitz AJ; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2014 Sep; 155(9):1793-1801. PubMed ID: 24937440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials.
    Lian J; Wang J; Li X; Yang S; Li H; Zhong Y; Gao H; Chen G
    Clin Neuropharmacol; 2023 Jan-Feb 01; 46(1):6-16. PubMed ID: 36542785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tanezumab in the treatment of chronic low back pain.
    Katz N; Borenstein DG; Birbara C; Bramson C; Nemeth MA; Smith MD; Brown MT
    Pain; 2011 Oct; 152(10):2248-2258. PubMed ID: 21696889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis.
    Fallon M; Sopata M; Dragon E; Brown MT; Viktrup L; West CR; Bao W; Agyemang A
    Oncologist; 2023 Dec; 28(12):e1268-e1278. PubMed ID: 37343145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial.
    Markman JD; Schnitzer TJ; Perrot S; Beydoun SR; Ohtori S; Viktrup L; Yang R; Bramson C; West CR; Verburg KM
    Pain Ther; 2022 Dec; 11(4):1267-1285. PubMed ID: 35962939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome.
    Nickel JC; Atkinson G; Krieger JN; Mills IW; Pontari M; Shoskes DA; Crook TJ
    Urology; 2012 Nov; 80(5):1105-10. PubMed ID: 23010344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.
    Nagashima H; Suzuki M; Araki S; Yamabe T; Muto C;
    Osteoarthritis Cartilage; 2011 Dec; 19(12):1405-12. PubMed ID: 22004765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.
    Da JLW; Merker VL; Jordan JT; Ly KI; Muzikansky A; Parsons M; Wolters PL; Xu L; Styren S; Brown MT; Plotkin SR
    Contemp Clin Trials; 2022 Oct; 121():106900. PubMed ID: 36038003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tanezumab in the treatment of pain from bone metastases.
    Sopata M; Katz N; Carey W; Smith MD; Keller D; Verburg KM; West CR; Wolfram G; Brown MT
    Pain; 2015 Sep; 156(9):1703-1713. PubMed ID: 25919474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis.
    Brown MT; Sandroni P; Low PA; Gorson KC; Hunter DJ; Pixton GC; Fountaine RJ; Viktrup L; West CR; Verburg KM
    J Neurol Sci; 2022 Mar; 434():120184. PubMed ID: 35217440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.
    Dakin P; Kivitz AJ; Gimbel JS; Skrepnik N; DiMartino SJ; Emeremni CA; Gao H; Stahl N; Weinreich DM; Yancopoulos GD; Geba GP
    Ann Rheum Dis; 2021 Apr; 80(4):509-517. PubMed ID: 33199274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.